Precision Medicine in the Treatment of Epilepsy
ConditionEpilepsy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-55
SponsorGitte Moos Knudsen
About this trial
Primary objectives:
The purpose of this study is to identify single and composite biomarkers (from neuroimaging, electrophysiological, and non-imaging biological measures), clinical measures (from cognitive, psychometric, and behavioral test scores), and risk/protective factors (e.g., from medical history, socioeconomic status, coping, lifestyle) that can:
1. Predict antiseizure medication (ASM) treatment outcome, psychiatric, cognitive, or behavioral comorbidities, and quality of life in newly diagnosed epilepsy patients (Cohort II-III). 2. Predict a second epileptic seizure/epilepsy diagnosis and behavioral, cognitive, psychiatric dysfunction and quality of life in patients after a first epileptic seizure (Cohort I).
Eligibility criteria
Qualifiers
No history of current or past psychiatric or other major medical conditions
Disqualifiers
Current or previous neurological disease, severe somatic disease, or consumption of medical drugs likely to influence the test results
Non-fluent in Danish or pronounced visual or auditory impairments
Current or past learning disability
Pregnancy or lactation (females)
Trial design
Treatments tested in this trial
- Levetiracetam
- Levetiracetam Tablets
- Lamotrigine tablet
Treatment groups
550 Participants
are divided into 4 treatment groupsSponsors and collaborators
Gitte Moos Knudsen
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution
Source ClinicalTrials.gov